Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis

The glucagon-like peptide-1 receptor agonists (GLP-1RA) are among the newest treatment options available for managing of type 2 diabetes mellitus and slowing the progression of diabetes kidney disease (DKD). Subcutaneous (SC) semaglutide (Ozempic<sup>®</sup>) is a GLP-1RA with an extende...

Descripción completa

Detalles Bibliográficos
Autores principales: De la Flor, José C., Lorenzo, Javier Deira, Marschall, Alexander, Valga, Francisco, Vázquez, Tania Monzón, Cícero, Elisa Ruiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710441/
https://www.ncbi.nlm.nih.gov/pubmed/36465574
http://dx.doi.org/10.1159/000527919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710441/
https://www.ncbi.nlm.nih.gov/pubmed/36465574
http://dx.doi.org/10.1159/000527919

Ejemplares similares